546 completed, 65 unknown, 52 terminated, 24 withdrawn. 724 Phase 3, 74 Phase 2.
Follow Hepatitis: new trials by email Literature Review of Hepatitis trials Research Report on Hepatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D Hepalatide 2.1mg, Placebo of Hepalatide - Hepatitis D, Chronic | Phase 3 | Not yet recruiting | Shanghai HEP Pharmaceutical Co., Ltd. | 150 | 2027-06-01 | 2026-10-28 |
| A Trial of Inebilizumab in Participants With Autoimmune Hepatitis Inebilizumab, Placebo, Standard of Care - Autoimmune Hepatitis, AIH | Phase 3 | Recruiting | Amgen | 180 | 2026-12-18 | 2026-11-03 |
| Study Interchangeability Hep-B Vaccine Administered at Birth Dose In-house Hepatitis B Vaccine, Registered Hepatitis B Vaccine - Vaccination Adverse Event, Immunogenicity, Vaccine | Phase 3 | Not yet recruiting | PT Bio Farma | 270 | 2026-10-01 | 2026-10-02 |
| Study of BK1803 in Healthy Infants BK1803, GOBIK Aqueous Suspension Syringes, Bimmugen® Injection - Pertussis, Diphtheria | Phase 3 | Not yet recruiting | Tanabe Pharma Corporation | 344 | 2026-10-01 | 2026-08-28 |
| Treatment of CKD Patients With HCV SOF+DCV, OBV/PTV/r) ± ribavirin (RBV) - HCV Infection ( Genotype 4) in CKD Patients | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 50 | 2026-09-15 | 2026-08-20 |
| Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response TQA3605 tablets Placebo, TQA3605 tablets, Entecavir dispersible tablets - Chronic Hepatitis B | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 930 | 2026-09-01 | 2026-10-02 |
| Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP, 3P mHealth package - HIV Infection, Sexually Transmitted Infection | Phase 3 | Not yet recruiting | HIV Prevention Trials Network | 400 | 2026-09-01 | 2026-06-22 |
| Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A Vaccine Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL), Inactivated Hepatitis A Vaccine (Human Diploid Cell) (0.5 mL), Hepatitis A vaccine (inactivated, adsorbed) - Hepatitis A Vaccine | Phase 3 | Recruiting | Sinovac Biotech Co., Ltd | 680 | 2026-08-20 | 2026-08-28 |
| Phase IIIB Extension Clinical Trial of Efficacy and Safety of GST-HG141 (Nairevir) Combined With NAs in Chronic Hepatitis B GST-HG141 - Chronic Hepatitis b | Phase 3 | Not yet recruiting | Fujian Akeylink Biotechnology Co., Ltd. | 576 | 2026-06-26 | 2026-05-14 |
| PROlonged Corticosteroid Treatment or N-ACetylcysteine for Severe Alcoholic Hepatitis N-Acetylcysteine (NAC) Treatment, Prednisolone, Placebo of N-acetylcysteine - Alcoholic Hepatitis | Phase 3 | Recruiting | University Hospital, Lille | 477 | 2026-05-22 | 2026-06-01 |
| A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study) Libevitug 20 mg/kg, Libevitug 10 mg/kg, Delayed treatment with libevitug - Chronic Hepatitis D Infection | Phase 3 | Recruiting | Huahui Health | 160 | 2026-04-22 | 2026-08-24 |
| Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide Brelovitug (BJT-778), Bulevirtide - Chronic Hepatitis D | Phase 2 / Phase 3 | Recruiting | Mirum Pharmaceuticals, Inc. | 120 | 2026-02-26 | 2026-10-27 |
| Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) Larsucosterol, Placebo - Hepatitis | Phase 3 | Recruiting | Bausch Health Americas, Inc. | 350 | 2026-01-29 | 2026-10-15 |
| A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg - Chronic Hepatitis D Infection | Phase 3 | Active not recruiting | Mirum Pharmaceuticals, Inc. | 80 | 2026-01-14 | 2026-06-29 |
| Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) Recombinant Hepatitis B new Bulk vaccine, DTP-HB-Hib with Recombinant Hepatitis B new Bulk vaccine, Recombinant Hepatitis B vaccine (Registered BioFarma) - Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction | Phase 3 | Withdrawn | PT Bio Farma | 2025-12-01 | 2025-06-05 | |
| Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III) In-House Recombinant Hepatitis B (Bio Farma) vaccine, Registered Hepatitis B vaccine recombinant (Engerix-B) - Vaccine Reaction, Vaccine Adverse Reaction | Phase 3 | Not yet recruiting | PT Bio Farma | 540 | 2025-09-01 | 2025-06-06 |
| A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B AZVUDINE, TAF, IFNα-2a - Chronic Hepatitis B, Azvudine | Phase 3 | Recruiting | Zhigang Ren | 120 | 2025-09-01 | 2025-12-29 |
| A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mg - Chronic Hepatitis D Infection | Phase 3 | Recruiting | Mirum Pharmaceuticals, Inc. | 172 | 2025-08-27 | 2026-10-08 |
| Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) AHB-137, Placebo, NA therapy - Chronic Hepatitis B | Phase 3 | Active not recruiting | Ausper Biopharma Co., Ltd. | 577 | 2025-08-12 | 2026-05-04 |
| A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB ZM-H1505R 100mg, ZM-H1505R Placebo, NAs （"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"or"TMF"） treatments - Chronic Hepatitis B | Phase 3 | Not yet recruiting | Shanghai Zhimeng Biopharma, Inc. | 1300 | 2025-08-01 | 2025-08-03 |
Showing 20 of 724. Sign in to see all of them.
Hepatitis C (284) · Hepatitis C, Chronic (201) · Hepatitis B (195) · Hepatitis B, Chronic (85) · Diphtheria (57) · Tetanus (56) · Haemophilus Infections (47) · Whooping Cough (44) · Fibrosis (37) · Poliomyelitis (37) · HIV Infections (26) · Hepatitis A (21) · Hepatitis, Alcoholic (20) · Liver Diseases (19)
Digestive System Diseases (718) · Liver Diseases (705) · Infections (674) · Hepatitis, Viral, Human (668) · Virus Diseases (662) · Blood-Borne Infections (651) · Communicable Diseases (648) · RNA Virus Infections (475) · Flaviviridae Infections (389) · Pathological Conditions, Signs and Symptoms (341) · Pathologic Processes (337) · Disease Attributes (310) · Chronic Disease (302) · Hepatitis, Chronic (292)
Ribavirin (201) · peginterferon alfa-2a (104) · peginterferon alfa-2b (61) · Sofosbuvir (49) · Tenofovir (37) · daclatasvir (32) · ombitasvir (32) · paritaprevir (30) · glecaprevir and pibrentasvir (28) · dasabuvir (27) · Hepatitis B Vaccines (25) · entecavir (24) · telaprevir (23) · glecaprevir (22) · Engerix-B (21)
GlaxoSmithKline (68) · Merck Sharp & Dohme LLC (60) · Gilead Sciences (53) · AbbVie (48) · Bristol-Myers Squibb (39) · Sanofi Pasteur, a Sanofi Company (25) · Hoffmann-La Roche (15) · French National Agency for Research on AIDS and Viral Hepatitis (11) · Boehringer Ingelheim (10) · Novartis Pharmaceuticals (10) · Janssen R&D Ireland (9) · Tanabe Pharma Corporation (9) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (8) · Foundation for Liver Research (7) · Novartis (7)
United States (188) · France (114) · Canada (111) · Germany (97) · Spain (94) · United Kingdom (88) · Italy (76) · Australia (73) · Belgium (65) · South Korea (64) · China (62) · Puerto Rico (59) · Poland (53) · Russia (53) · Taiwan (49)
PMID 30977945, PMID 30012435, PMID 30923816, PMID 31568620, PMID 29461687, PMID 30529905, PMID 29377566, PMID 29404492, PMID 28193518, PMID 25040192, PMID 25583164, PMID 27847279, PMID 30868245, PMID 35174470, PMID 37771546, PMID 25445400, PMID 26743093, PMID 26947564, PMID 27553375, PMID 36740893, PMID 16026887, PMID 17716936, PMID 19052126, PMID 19553649, PMID 20189674, PMID 20955704, PMID 22239511, PMID 22626609, PMID 23234725, PMID 23364953, PMID 23607593, PMID 23607594, PMID 23939953, PMID 24126097, PMID 25179493, PMID 25196718, PMID 25277773, PMID 25532501, PMID 25710287, PMID 25777337, PMID 25788199, PMID 25987775, PMID 26173631, PMID 26321288, PMID 26575258, PMID 26683763, PMID 26936417, PMID 27049487, PMID 27658343, PMID 27920566
2015 (23), 2014 (22), 2016 (10), 2004 (6), 2008 (4), 2009 (4), 2005 (3), 2017 (3), 2025 (3), U01DK082843 (3), U01DK082864 (3), U01DK082871 (3), U01DK082874 (3), U01DK082944 (3), UL1TR000004 (3)